← Back to Search

NMDA Receptor Antagonist

IV Ketamine for Suicidal Ideation

Phase 3

Waitlist Available

Research Sponsored by University of Ottawa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

Study Summary

This trial aims to study rapid treatment of suicidal ideation in adolescents with ketamine, which could help reduce emergency visits & lengthy admissions, and improve how we treat mental health emergencies.

Who is the study for?

This trial is for adolescents aged 12-17 who are experiencing moderate to severe suicidal thoughts and have been medically cleared. They must speak English or French, and not be on certain medications or have specific health conditions like epilepsy, stroke history, severe hypertension, or cardiac issues.Check my eligibility

What is being tested?

The study tests if IV ketamine can quickly reduce suicidal thoughts in adolescents visiting the emergency department. It compares the effects of ketamine with a saline solution (placebo) to see if it can provide rapid relief until long-term psychiatric care begins.See study design

What are the potential side effects?

While not specified here, common side effects of ketamine may include disorientation, dizziness, nausea, increased blood pressure and heart rate changes. These vary from person to person.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of the study as measured by the percentage of eligible of patients able to complete the study protocol.

Secondary outcome measures

Admission to Hospital

Feeling suicidal (finding)

Mental Depression

+10 more

Side effects data

From 2020 Phase 4 trial • 75 Patients • NCT03156504

Lightheadedness with low blood pressure

Pump Malfunction

PTSD

100%

80%

60%

40%

20%

Study treatment Arm

Ketamine

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Intravenous ketamine infusionExperimental Treatment1 Intervention

Participants in the intervention group will receive 0.5mg/kg of 1mg/mL intravenous ketamine (50 mg maximum) over 40 minutes.

Group II: Intravenous normal saline infusionPlacebo Group1 Intervention

Participants in the control group will receive 0.5mL/kg intravenous normal saline (50 ml maximum) over 40 minutes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine Hydrochloride

2018

Completed Phase 4

~910

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of OttawaLead Sponsor

205 Previous Clinical Trials

266,071 Total Patients Enrolled

Media Library

Ketamine Hydrochloride (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05468840 — Phase 3

Suicidal Thoughts Research Study Groups: Intravenous normal saline infusion, Intravenous ketamine infusion

Suicidal Thoughts Clinical Trial 2023: Ketamine Hydrochloride Highlights & Side Effects. Trial Name: NCT05468840 — Phase 3

Ketamine Hydrochloride (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05468840 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Intravenous ketamine infusion been sanctioned by the FDA?

"Data collected from this Phase 3 trial has demonstrated a high level of safety with Intravenous ketamine infusion, thus it received an assessment score of 3."

Answered by AI

Is this experiment accepting senior citizens as participants?

"According to this study's inclusion criteria, adolescents between 12 and 17 years old are eligible participants. There are 67 trials for minors and 225 clinical studies available for elderly individuals."

Answered by AI

Are any slots remaining for those wishing to join this research endeavor?

"The data on clinicaltrials.gov suggests that this medical trial is no longer actively seeking new patients, as the study was first posted on June 1st of 2023 and last updated February 8th of the same year. Nevertheless, there are still 296 other trials recruiting participants at present."

Answered by AI

Are there certain applicants who are more suitable for this experiment?

"The trial is enrolling 20 adolescents between 12 and 17 years old that express suicidal ideation, as judged by the ASQ questionnaire at triage. Furthermore, participants must score a minimum of 3 on the SSI5 Beck Scale for Suicidal Ideation, be able to communicate in either English or French, and have been medically cleared by their attending physician."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

Michael Schlegelmilch 2023. "Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05468840.